Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
AstraZeneca's drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestor, although the pace of decline slowed as it looks to new cancer treatments to revive its fortunes.
Product sales were down 3 percent compared with an 11 percent fall during the first half of the year. Emerging markets proved a bright spot, with Chinese sales up 12 percent, the company said on Thursday.
Chief Executive Pascal Soriot believes the drugmaker has reached a turning-point as its pipeline of new medicines starts to deliver and the impact of patent losses recedes. Consensus forecasts also point to a recovery in sales and profits from next year.
Still, the speed of AstraZeneca's turnaround remains uncertain as the No. 2 British drugmaker goes head to head with industry giants like Roche, Bristol-Myers Squibb, and Merck in the fast-growing but fiercely competitive cancer drug market.
Total revenue rose 9 percent to $6.23 billion in the quarter, helped by a $997 million payment from Merck, which struck a cancer drug partnership deal with the British group in July. Sales of Crestor, while down 16 percent, were also higher than expected.
That was not enough to stop a fall in core earnings per share (EPS), which exclude some items, of 15 percent to $1.12. But the overall results were better than expected and the shares had risen around 1 percent by 1130 GMT.
Industry analysts, on average, had forecast quarterly earnings of $1.04 and revenue of $5.95 billion, according to Thomson Reuters data.
For the full year, AstraZeneca said it expected 2017 core EPS to be "towards the favorable end of the guidance range of a low to mid-teens percentage decline".
Soriot said he remained confident AstraZeneca could achieve annual revenue of more than $40 billion in 2023, despite skepticism among analysts like Trinity Delta's Mick Cooper who said it was "difficult" to see how this would be done.
Soriot first gave a bullish long-term forecast of 2023 revenue hitting $45 billion back in 2014, as he fended off a takeover attempt by Pfizer. Since then, a stronger dollar has shifted the target slightly but Soriot said the expectation in constant exchange rates had not changed.
"Our long-range plan so far reconfirms that we can get to the $40 billion to 41 billion dollars at today's currency rates that we communicated back in 2014," he said.
Results from drug trials remain critical.
AstraZeneca suffered the biggest ever daily fall in its shares three months ago, following the initial failure of a key lung cancer trial dubbed Mystic.
But it has since rebuilt investor expectations, helped by impressive data from two other lung cancer trials, involving the drugs Tagrisso and Imfinzi, that were presented at a medical congress in Madrid in September.
And just last week it won early U.S. approval for Calquence, marking its first entry into the blood cancer market.
However, results from another immunotherapy lung cancer trial called Arctic have been delayed again and are now not expected until the first half of 2018.
AstraZeneca is also refilling its drug pipeline in other areas, such as respiratory medicine. A new drug for severe asthma is awaiting U.S. approval by the end of this year and could get an approval recommendation in Europe as early as Friday.